Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.APR Applied Pharma Research and its development partner Labtec have entered into an exclusive licensing agreement with Ferrer Internacional for the promotion, distribution and marketing of Alzheimer drug Donepezil Oral Dispersible Film (ODF) in Spain, Portugal and Germany.
Subscribe to our email newsletter
Donepezil ODF is an oral thin film formulation for the symptomatic treatment of Alzheimer’s disease and other types of dementia.
Following Ondasetron ODF, Donepezil ODF is the second licensed candidate of a broad development pipeline of ODF prescription products based upon APR/Labtec’s proprietary Rapidfilm technology, APR said.
APR CEO Paolo Galfetti said that the future of many molecules to become off-patent such as Donepezil will be determined by dosage form diversification and patient compliance. ODF certainly is the oral dosage form contributing the most to compliance by ensuring drug delivery while being easy to use without any discomfort for patients and doctors.
Ferrer is a privately held European R&D-based pharmaco-chemical and medical device company headquartered in Barcelona, Spain.
Switzerland-based APR develops and licenses patented healthcare products and proprietary drug delivery systems primarily in the oral and topical fields.
Labtec, which became a subsidiary of tesa SE in 2008, focuses in transdermal and topical patch arena.